- Significant efficacy differences widen 6 weeks after treatment stops -
SAN FRANCISCO, March 10 /PRNewswire/ -- A nonprescription topical solution made with a new formulation of liquor carbonis distillate (LCD), known as PSORENT(R), is significantly more effective than prescription-strength calcipotriol cream in improving and controlling the symptoms of plaque psoriasis, according to research findings presented at the American Academy of Dermatology's 2009 Annual Meeting. Significant efficacy differences favoring LCD solution over a 12-week treatment phase were also pronounced after treatment stopped, during a 6-week regression phase that was the focus of the today's presentation. The research, a randomized, investigator-blind, active-controlled study of 60 adults with moderate plaque psoriasis, was conducted by a team of investigators at the Clinical Unit for Research Trials in Skin (CURTIS) at Massachusetts General Hospital in Boston, Massachusetts.
"We knew, based on the preliminary study results we presented at the summer AAD, that in the treatment phase of this study, twice-daily LCD outperformed calcipotriol cream for control of psoriasis symptoms," said Alexa Kimball, MD, MPH, a CURTIS researcher who was also a study investigator and author. "But we were encouraged by the fact that the improvements also persisted longer after patients stopped their twice-daily treatments for six weeks."
The team's conclusions are based on data from 55 patients who received treatment for up to 12 weeks and 43 patients who returned for re-assessment 6 weeks after treatment stopped. Its main findings include:
| SOURCE NeoStrata Company, Inc. Copyright©2009 PR Newswire. All rights reserved |